VolitionRX (VNRX)
:VNRX
Want to see VNRX full AI Analyst Report?
VNRX Stock Chart & Stats
$0.18
$0.01(1.52%)
At close: 4:00 PM EST
$0.18
$0.01(1.52%)
Day’s Range― - ―
52-Week Range$1.30 - $18.78
Previous CloseN/A
Volume29.92K
Average Volume (3M)19.46M
Market Cap
$11.73M
Enterprise Value$22.60M
Total Cash (Recent Filing)$3.10M
Total Debt (Recent Filing)$11.42M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Aug 19, 2026EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.25
Shares Outstanding8,627,191
10 Day Avg. Volume55,156,196
30 Day Avg. Volume19,458,360
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-0.80
Price to Sales (P/S)15.80
P/FCF Ratio-1.38
Enterprise Value/Market Cap1.93
Enterprise Value/Revenue9.16
Enterprise Value/Gross Profit10.22
Enterprise Value/Ebitda-1.14
Forecast
1Y Price Target
$22.00Price Target Upside12122.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.41
Revenue Forecast (FY)$6.87M
Bulls Say, Bears Say
Bulls Say
Capture-Seq Early Detection & IPCapture-Seq's reported >95% detection in an early blinded cohort, accompanied by patent filings and strong preprint interest, indicates a differentiated technological capability and emerging IP moat. If validated in larger studies, this supports durable product leadership in early cancer detection and licensing opportunities that can scale beyond single revenue events.
Improving Revenue TrendSustained double-digit revenue growth from a small base shows the company is beginning to commercialize its Nu.Q assays and expand customer adoption. Over 2–6 months this trend suggests rising commercial traction, enabling incremental margin leverage if revenue continues to diversify across products and partners rather than one-off recognitions.
Product Diversification & Partner MilestonesValidated Vet automation with a major instrument partner and a contractually linked $5M milestone demonstrate concrete commercialization pathways outside human diagnostics. Diversified streams (veterinary, research reagents, commercial partnerships) reduce single-market dependency and create multiple channels for recurring revenue and milestone-driven cash inflows over the medium term.
Bears Say
Negative Shareholders' EquityPersistently negative equity signals accumulated losses that materially weaken financial flexibility. This limits access to non-dilutive capital, elevates creditor and covenant risk, and constrains the company's ability to fund commercial scale-up or absorb setbacks without dilutive financings or onerous covenant concessions, a structural headwind to long-term stability.
High Cash Burn / Weak Cash GenerationLarge negative operating and free cash flows indicate the business cannot self-fund growth. Continued high cash burn forces reliance on external financing, which can be dilutive or restrictive and may divert management focus to fundraising. Without material, predictable revenue uplift or recurring partner payments, runway and strategic execution remain at risk.
Lumpy Revenue & Milestone DependenceRevenue timing driven by deferred recognition and milestone triggers undermines predictability needed for sustainable operating planning. Dependence on milestone payments and partner validation makes margins and cash flow volatile, complicating scaling decisions and reducing the reliability of revenue forecasts for multi-period investment and commercialization execution.
VolitionRX News
VNRX FAQ
What was VolitionRX’s price range in the past 12 months?
VolitionRX lowest stock price was $1.30 and its highest was $18.78 in the past 12 months.
What is VolitionRX’s market cap?
VolitionRX’s market cap is $11.73M.
When is VolitionRX’s upcoming earnings report date?
VolitionRX’s upcoming earnings report date is Aug 19, 2026 which is in 69 days.
How were VolitionRX’s earnings last quarter?
Currently, no data Available
Is VolitionRX overvalued?
According to Wall Street analysts VolitionRX’s price is currently Undervalued.
Does VolitionRX pay dividends?
VolitionRX does not currently pay dividends.
What is VolitionRX’s EPS estimate?
VolitionRX’s EPS estimate is -0.62.
How many shares outstanding does VolitionRX have?
VolitionRX has 8,627,191 shares outstanding.
What happened to VolitionRX’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VolitionRX?
Currently, no hedge funds are holding shares in VNRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VolitionRX
VolitionRx Limited is an international epigenetics firm that specializes in pioneering advanced blood tests. These diagnostics are developed to aid in the global detection of various cancers and other diseases. Their innovative product suite includes Nu.Q, engineered for cancer detection; Nu.Q Nets, which monitors immune system health; Nu.Q Vet, a cancer screening solution tailored for animal applications; Nu.Q Capture, designed to enhance diagnostic precision by concentrating samples; and Nu.Q Discover, a specialized platform for nucleosome profiling. The cornerstone of their blood test technology is their proprietary Nucleosomics platform. The company maintains its headquarters in Austin, Texas.
VNRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented substantial scientific and commercial progress across multiple product pillars (Nu.Q Vet automation and feline assay, Nu.Q NETs publications and point-of-care finger-prick breakthrough, Capture-Seq >99% pure ctDNA claims, Nu.Q Discover expansion), alongside improving headline revenue (+300% YoY) and a stronger quarter-end cash balance driven by financing and grants. However, important caveats include revenue lumpiness driven in part by deferred recognition, rising operating expenses and cash burn, reliance on milestone payments and external financing, and the need for broader validation, publications, and regulatory/reimbursement approvals to convert technical advances into predictable commercial revenue. On balance, the call signals strong technical momentum and growing commercial interest but with execution and timing risks to monetize those advances in the near term.View all VNRX earnings summariesVNRX Stock 12 Month Forecast
Average Price Target
$22.00
▲(12122.22% Upside)
Technical Analysis
Ownership Overview
9.74% Insiders
1.15% Mutual Funds
― Other Institutional Investors
88.47% Public Companies and
Individual Investors